Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

Jamie Kelter Davis / Bloomberg via Getty Images AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two ...

AbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets.

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

Gifting allows recipients to access the article for free. AbbVie Inc. rose the most in just over four years after it forecast 2025 earnings above Wall Street’s average expectation as two key ...

AbbVie expects full-year earnings in the range of $12.12 to $12.32 per share. AbbVie shares have fallen 1% since the beginning of the year, while the S&P’s 500 index has increased 27%. The stock ...